News | April 06, 2022
Revenue growth to moderate, non-Covid-19 revenue to drive profitability
Ind-Ra maintains a neutral outlook for healthcare in FY23
Ind-Ra maintains a neutral outlook for healthcare in FY23
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Key takeaways of Q3FY22 quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Subscribe To Our Newsletter & Stay Updated
